Moderna, Inc.: Moderna Announces Advances Across mRNA Pipeli

COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Japan , United States , Japanese , Mary Beth Woodin , Lavina Talukdar , Vertex Pharmaceuticals , Drug Administration , Nasdaq , Exchange Commission , Moderna Inc View , Moderna Inc , Summary Of Program Updates , Wrd Communications , Chief Executive Officer , Flu Phase , Advance Purchase Agreements , Moderna Rd Day , Open Label Extension , Investigational New Drug , Oriciro Genomics , Cytomx Therapeutics , Carisma Therapeutics , Priority Review Voucher , Analyst Event , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Vice President , Inc View , Moderna , Nnounces , Advances , Cross , Rna , Pipeline , Rovides , Business , Update ,